LENZ Therapeutics, Inc. LENZ
LENZ Therapeutics, Inc. (Nasdaq: LENZ) is an ophthalmology drug developer. Its lead program, VIZZ (aceclidine ophthalmic solution) 1.44%, is marketed for Presbyopia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VIZZ (aceclidine ophthalmic solution) 1.44% | Presbyopia | small molecule | Approved |
Recent results and decisions
- Sep 1, 2026submitted MAA submitted for presbyopia treatment in Vietnam under Lotus Pharmaceutical agreement.
In August and September 2026, under the licensing and commercialization agreement with Lotus Pharmaceutical, the MAA was submitted for the treatment of presbyopia in Malaysia and Vietnam, respectively.
Filing - Aug 1, 2026submitted MAA submitted for presbyopia treatment in Malaysia under Lotus Pharmaceutical agreement.
In August and September 2026, under the licensing and commercialization agreement with Lotus Pharmaceutical, the MAA was submitted for the treatment of presbyopia in Malaysia and Vietnam, respectively.
Filing - Jul 1, 2026submitted MAA submitted to Saudi Food and Drug Authority under Lunatus distribution agreement for presbyopia treatment in the Kingdom of Saudi Arabia.
In July 2026, under the exclusive distribution agreement with Lunatus for the Middle East region, the MAA was submitted under the Saudi Food and Drug Authority's Abridged Pathway for the treatment of presbyopia in the Kingdom of Saudi Arabia.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved ophthalmology companies
- Harrow, Inc. HROW
- Sight Sciences, Inc. SGHT
- Outlook Therapeutics, Inc. OTLK
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.